Immatics to receive $60M up front & additional fees for certain activities, ~$700M in development, regulatory & commercial milestones along with royalty. Both companies get an option to develop ~4 additional programs
The collaboration will use Immatics’ gamma delta T cell-derived ACTallo platform with BMS’ expertise to develop allogeneic TCR-T/CAR-T programs. Immatics will lead the preclinical development of the 2 initial programs & BMS will lead the clinical development & commercialization activities of all BMS-owned programs
Additionally, BMA expands its 2019 agreement with Immatics for autologous TCR-T with 1 additional TCR target where Immatics will receive $20M up front & milestones along with royalties
Ref: Businesswire | Image: BMS
